15203-Lung Cancer-NSCLC-1278

Lung Cancer

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384)

  • Details

ClinicalTrials.gov ID: NCT02713867
Diagnosis Type: NSCLC
USOR Number: 15203

  • Address

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.